These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 8644655)

  • 1. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.
    Lefkovits J; Ivanhoe RJ; Califf RM; Bergelson BA; Anderson KM; Stoner GL; Weisman HF; Topol EJ
    Am J Cardiol; 1996 May; 77(12):1045-51. PubMed ID: 8644655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. Evaluation of c7E3 for the Prevention of Ischemic Complications.
    Lefkovits J; Blankenship JC; Anderson KM; Stoner GL; Talley JD; Worley SJ; Weisman HF; Califf RM; Topol EJ
    J Am Coll Cardiol; 1996 Oct; 28(4):849-55. PubMed ID: 8837559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
    Ghaffari S; Kereiakes DJ; Lincoff AM; Kelly TA; Timmis GC; Kleiman NS; Ferguson JJ; Miller DP; Califf RA; Topol EJ
    Am J Cardiol; 1998 Jul; 82(1):7-12. PubMed ID: 9671000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators.
    Topol EJ; Califf RM; Weisman HF; Ellis SG; Tcheng JE; Worley S; Ivanhoe R; George BS; Fintel D; Weston M
    Lancet; 1994 Apr; 343(8902):881-6. PubMed ID: 7908357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
    Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ
    J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators
    N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
    Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ
    Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
    Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
    Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication.
    Topol EJ; Ferguson JJ; Weisman HF; Tcheng JE; Ellis SG; Kleiman NS; Ivanhoe RJ; Wang AL; Miller DP; Anderson KM; Califf RM
    JAMA; 1997 Aug; 278(6):479-84. PubMed ID: 9256222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of platelet glycoprotein IIb/IIIa receptor inhibition on distal embolization during percutaneous revascularization of aortocoronary saphenous vein grafts. EPIC Investigators. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
    Mak KH; Challapalli R; Eisenberg MJ; Anderson KM; Califf RM; Topol EJ
    Am J Cardiol; 1997 Oct; 80(8):985-8. PubMed ID: 9352964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ; Barr LA; Burchenal JE; Katz S; George BS; Jones AA; Cohen ED; Gainey PC; White HJ; Cheek HB; Moses JW; Moliterno DJ; Effron MB; Topol EJ
    Circulation; 1998 Aug; 98(8):734-41. PubMed ID: 9727542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
    Mark DB; Talley JD; Topol EJ; Bowman L; Lam LC; Anderson KM; Jollis JG; Cleman MW; Lee KL; Aversano T; Untereker WJ; Davidson-Ray L; Califf RM
    Circulation; 1996 Aug; 94(4):629-35. PubMed ID: 8772681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial.
    Moliterno DJ; Califf RM; Aguirre FV; Anderson K; Sigmon KN; Weisman HF; Topol EJ
    Am J Cardiol; 1995 Mar; 75(8):559-62. PubMed ID: 7887377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefit of glycoprotein IIb/IIIa blockade with Abciximab is independent of gender: pooled analysis from EPIC, EPILOG and EPISTENT trials. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation in Percutaneous Transluminal Coronary Angioplasty to Improve Long-Term Outcome with Abciximab GP IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stent.
    Cho L; Topol EJ; Balog C; Foody JM; Booth JE; Cabot C; Kleiman NS; Tcheng JE; Califf R; Lincoff AM
    J Am Coll Cardiol; 2000 Aug; 36(2):381-6. PubMed ID: 10933346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial. EPIC Investigators. Evaluation of IIb/IIIa Platelet Receptor Antagonist 7E3 in Preventing Ischemic Complications.
    Khan MM; Ellis SG; Aguirre FV; Weisman HF; Wildermann NM; Califf RM; Topol EJ; Kleiman NS
    J Am Coll Cardiol; 1998 Jan; 31(1):31-6. PubMed ID: 9426014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
    Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
    Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.